The US Food and Drug Administration (FDA) has approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a rare autoimmune disorder that affects the connection between nerves and muscles and causes weakness and other symptoms in affected patients. This is the first FDA approval of a treatment for LEMS.
The FDA granted the approval of Firdapse to Catalyst Pharmaceuticals, Inc., headquartered in Coral Gables, FL.
Indications: Firdapse is a potassium channel blocker indicated for the treatment of
LEMS in adults.
Dosage/administration: The recommended starting dosage is 15 mg to 30 mg daily taken orally
in divided doses (3 to 4 times daily). Starting dosage is 15 mg daily for patients with renal impairment, hepatic impairment, and in known N-acetyltransferase 2 (NAT2) poor metabolizers. Dosage can be increased by 5 mg daily every 3 to 4 days, but is not to exceed a maximum of 80 mg daily. The maximum single dose is 20 mg.
Adverse reactions: The most common (> 10%) adverse reactions are: paresthesia, upper
respiratory tract infection, abdominal pain, nausea, diarrhea, headache, elevated liver enzymes, back pain, hypertension, and muscle spasms.
FDA approves first treatment for Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder. [news release]. Coral Gables, Florida: Catalyst Pharmaceuticals, Inc. November 28, 2018. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/UCM627093.htm?utm_campaign=11282018_PR_FDA%20approves%20treatment%20for%20LEMS&utm_medium=email&utm_source=Eloqua. Accessed November 30, 2018.
Must Reads in FDA Actions
FDA Approves Firdapse for Rare Autoimmune Disorder, FDA news release; 2018 Nov 28
FDA Approves Ajovy for Migraine in Adults, Teva Pharmaceutical news release; 2018 Sep 14
FDA Approves Tiglutik for Treatment of ALS, ITF Pharma news release; 2018 Sep 6
FDA Approves Diacomit for Treatment of Seizures, Biocodex news release; 2018 Aug 23
FDA Approves Drug for Rare Peripheral Nerve Disease, FDA Web site; 2018 Aug 10